BACKGROUND: To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. DESIGN: interventional case series involving five patients (age: 42 +/- 14 years). METHODS: Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty). RESULTS: Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%). CONCLUSIONS: Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
BACKGROUND: To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization. DESIGN: interventional case series involving five patients (age: 42 +/- 14 years). METHODS:Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty). RESULTS:Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%). CONCLUSIONS:Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.
Authors: Sophie J Bakri; J Douglas Cameron; Colin A McCannel; Jose S Pulido; Ronald J Marler Journal: Am J Ophthalmol Date: 2006-07 Impact factor: 5.258
Authors: Claus Cursiefen; Jingtai Cao; Lu Chen; Ying Liu; Kazuichi Maruyama; David Jackson; Friedrich E Kruse; Stanley J Wiegand; M Reza Dana; J Wayne Streilein Journal: Invest Ophthalmol Vis Sci Date: 2004-08 Impact factor: 4.799
Authors: Felix Bock; Jasmine Onderka; Tina Dietrich; Björn Bachmann; Friedrich E Kruse; Matthias Paschke; Grit Zahn; Claus Cursiefen Journal: Invest Ophthalmol Vis Sci Date: 2007-06 Impact factor: 4.799
Authors: Yijun Cai; Jorge L Alio Del Barrio; Mark R Wilkins; Marcus Ang Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-10-08 Impact factor: 3.117